Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Alamar Biosciences, Inc.NASDAQ: ALMR
Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares (diluted) of 58.67M shares in Q2 FY2026
Q2 FY2026 weighted avg shares (diluted) was 58.67M shares.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 66.52M USD
- Year-over-year change
- —
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 66.52M | — |
Weighted Avg Shares (Diluted) vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's FY2025 weighted avg shares (diluted) of 66.52M shares is the 7th highest of the 9 companies compared; the peer median is 143.13M shares.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 384.09M | +2.7% | +69.5% | |
| LTM Mar 2026 | 302.18M | +5.2% | +10.1% | |
| LTM Mar 2026 | 201.73M | +31.6% | +12.4% | |
| LTM Sep 2026 | 157.22M | -0.4% | -1.0% | |
| LTM Sep 2026 | 129.04M | +4.4% | +3.1% | |
| LTM Mar 2026 | 126.35M | +0.5% | +0.4% | |
ALMRAlamar Biosciences, Inc. | FY2025 | 66.52M | — | — |
| LTM Sep 2026 | 61.95M | +3.1% | +3.3% | |
| LTM Mar 2026 | 56.96M | -7.5% | -2.7% | |
| Peer median (excluding ALMR) | 143.13M | +2.9% | +3.2% | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 74.21M |
| Cost of Revenue | 32.51M |
| Gross Profit | 41.71M |
| Gross Margin | 56.2% |
| Research & Development | 37.47M |
| Selling, General & Admin | 35.57M |
| Operating Expenses | 73.04M |
| Depreciation & Amortization | 3.86M |
| EBITDA | (24.89M) |
| EBITDA Margin | -33.5% |
| Operating Income | (31.33M) |
| Operating Margin | -42.2% |
| Interest Income | 2.16M |
| Interest Expense | 401K |
| Other Income / Expenses | 2.18M |
| Income Before Tax | (29.15M) |
| Pre-Tax Margin | -39.3% |
| Income Tax Expense | 665K |
| Net Income | (29.82M) |
| Net Margin | -40.2% |
| EPS (Basic) | (0.45) |
| EPS (Diluted) | (0.45) |
| Weighted Avg Shares | 66.52M |
| Weighted Avg Shares (Diluted) | 66.52M |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.